Is Moderna Stock a Buy or Sell After Johnson & Johnson's Vaccine News?
Moderna (NASDAQ: MRNA) and the Pfizer/BioNTech partnership might not enjoy a duopoly in the U.S. COVID-19 vaccine market for much longer. Johnson & Johnson (NYSE: JNJ) announced late-stage results for its coronavirus vaccine candidate last week. The healthcare giant now plans to seek Emergency Use Authorization (EUA) from the Food and Drug Administration.
Is Moderna stock a buy after J&J's announcement? Or is the more prudent move to sell the biotech stock? The answer is probably more complicated than you'd expect.
Image source: Getty Images.
Source Fool.com
